X4 PHARMACEUTICALS, INC Shareholders' Equity
X4 PHARMACEUTICALS, INC (XFOR) had Shareholders' Equity of $155.45 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $155.45M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $168.45M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $186.29M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $61.62M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $155.45M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $168.45M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $186.29M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $61.62M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $3.97M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $22.94M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $22.15M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $59.62M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $94.45M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $1.04M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $51.10M 10-K · filed 2026-03-17 | |
| 2023-09-30 | $67.59M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $67.53M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $51.68M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $74.05M 10-K · filed 2026-03-17 | |
| 2022-09-30 | $61.85M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $30.07M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $49.71M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $64.41M 10-K · filed 2025-03-26 | |
| 2021-09-30 | $68.68M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $87.34M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $105.06M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $72.80M 10-K · filed 2024-03-21 | |
| 2020-09-30 | $89.71M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $104.88M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $118.79M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $129.22M 10-K · filed 2023-03-21 | |
| 2019-09-30 | $79.11M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $96.17M 10-Q · filed 2020-11-05 | $96.17M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $29.44M 10-Q · filed 2020-11-05 | $29.44M 10-Q · filed 2019-05-15 |
| 2018-12-31 | -$77.09M 10-K · filed 2022-03-17 | $21.60M 10-K · filed 2019-03-11 |
| 2018-09-30 | -$66.09M 10-Q · filed 2019-11-07 | $27.90M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$57.69M 10-Q · filed 2019-11-07 | $37.76M 10-Q · filed 2018-08-13 |
| 2018-03-31 | -$51.81M 10-Q · filed 2019-11-07 | $48.42M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$44.55M 10-K · filed 2021-03-19 | $58.71M 10-Q · filed 2018-05-10 |
| 2016-12-31 | -$23.05M 10-K · filed 2020-03-12 | -$56.56M 10-K · filed 2019-03-11 |
| 2015-12-31 | -$34.32M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |